Company RepliCel Life Sciences Inc. Toronto S.E.
Equities
RP
CA76027P4006
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.055 CAD | -.--% |
|
-21.43% | -15.38% |
Business Summary
Number of employees: 1
Sales per Business
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell Replication Technology
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Sales per region
CAD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 18-12-13 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
David Kwok
DFI | Director of Finance/CFO | - | 23-08-15 |
David Hall
CHM | Chairman | 71 | 10-12-21 |
Ben Austring
COO | Chief Operating Officer | 41 | 22-11-27 |
Robert Buckler
BRD | Director/Board Member | 58 | 14-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 10-12-21 |
Peter Lewis
BRD | Director/Board Member | 69 | 11-05-26 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Robert Buckler
BRD | Director/Board Member | 58 | 14-09-30 |
Gary Boddington
BRD | Director/Board Member | 56 | 21-05-31 |
Andrew Schutte
CEO | Chief Executive Officer | 35 | 18-12-13 |
Jamie Mackay
BRD | Director/Board Member | - | 23-08-08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 61,426,772 | 24,249,871 ( 39.48 %) | 0 | 39.48 % |
Company contact information
RepliCel Life Sciences, Inc.
570 Granville Street Suite 900
V6C 3P1, Vancouver
+604 248 8730
http://www.replicel.com![address RepliCel Life Sciences Inc.(RP)](https://cdn.zonebourse.com/static/address/31799495.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+20.12% | 126B | |
+25.25% | 119B | |
+25.56% | 27.95B | |
-19.51% | 20.5B | |
-14.36% | 17.12B | |
-15.63% | 16.1B | |
-46.67% | 14.97B | |
+11.89% | 14.84B | |
+57.74% | 14.38B |
- Stock Market
- Equities
- REPCF Stock
- RP Stock
- Company RepliCel Life Sciences Inc.